• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Matinas Biopharma Holdings Inc. (Amendment)

    2/14/22 4:43:03 PM ET
    $MTNB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MTNB alert in real time by email
    SC 13G/A 1 d263184dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 4)*

     

     

    MATINAS BIOPHARMA HOLDINGS, INC.

    (Name of Issuer)

    Common Stock, par value $0.0001

    (Title of Class of Securities)

    576810105

    (CUSIP Number)

    December 31, 2021

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    Page 2 of 7

    CUSIP No. 576810105

     

      1    

      Name of reporting persons.

     

      Boxer Capital, LLC

      2  

      Check the appropriate box if a member of a group. (See instructions)

      (a)  ☐        (b)  ☒

     

      3  

      SEC use only.

     

      4  

      Citizenship or place of organization.

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5     

      Sole voting power.

     

      -0-

       6   

      Shared voting power.

     

      -0-

       7   

      Sole dispositive power.

     

      -0-

       8   

      Shared dispositive power.

     

      -0-

      9    

      Aggregate amount beneficially owned by each reporting person.

     

      -0-

    10  

      Check box if the aggregate amount in row (9) excludes certain shares (see instructions).

     

      ☐

    11  

      Percent of class represented by amount in row (9).

     

      0.0%

    12  

      Type of reporting person

     

      OO


    Page 3 of 7

    CUSIP No. 576810105

     

      1    

      Name of reporting persons.

     

      Boxer Asset Management Inc.

      2  

      Check the appropriate box if a member of a group. (See instructions)

      (a)  ☐        (b)  ☒

     

      3  

      SEC use only.

     

      4  

      Citizenship or place of organization.

     

      Bahamas

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5     

      Sole voting power.

     

      -0-

       6   

      Shared voting power.

     

      -0

       7   

      Sole dispositive power.

     

      -0-

       8   

      Shared dispositive power.

     

      -0-

      9    

      Aggregate amount beneficially owned by each reporting person.

     

      -0-

    10  

      Check box if the aggregate amount in row (9) excludes certain shares (see instructions).

     

      ☐

    11  

      Percent of class represented by amount in row (9).

     

      0.0%

    12  

      Type of reporting person

     

      CO


    Page 4 of 7

    CUSIP No. 576810105

     

      1    

      Name of reporting persons.

     

      Joe Lewis

      2  

      Check the appropriate box if a member of a group. (See instructions)

      (a)  ☐        (b)  ☒

     

      3  

      SEC use only.

     

      4  

      Citizenship or place of organization.

     

      United Kingdom

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5     

      Sole voting power.

     

      -0-

       6   

      Shared voting power.

     

      -0-

       7   

      Sole dispositive power.

     

      -0-

       8   

      Shared dispositive power.

     

      -0-

      9    

      Aggregate amount beneficially owned by each reporting person.

     

      -0-

    10  

      Check box if the aggregate amount in row (9) excludes certain shares (see instructions).

     

      ☐

    11  

      Percent of class represented by amount in row (9).

     

      0.0%

    12  

      Type of reporting person

     

      IN


    Page 5 of 7

     

    This Amendment No. 4 (“Amendment No. 4”) amends and supplements the statement on Schedule 13G filed on November 8, 2018 (the “Original Filing”) by Boxer Capital, LLC (“Boxer Capital”), Boxer Asset Management Inc. (“Boxer Management”) and Joe Lewis (together with Boxer Capital and Boxer Management, the “Reporting Persons”), as amended by Amendment No. 1 filed on February 14, 2019, Amendment No. 2 filed on February 14, 2020 and Amendment No. 3 filed on February 16, 2021. The Original Filing, as amended, remains in effect except to the extent that it is amended, restated or superseded by information contained in this Amendment No. 4. Capitalized terms used and not defined in this Amendment No. 4 have the meanings set forth in the Original Filing, as amended.

     

    Item 4.

    Ownership.

     

      (a)

    Amount beneficially owned:

    The Reporting Persons do not own any shares of Common Stock.

     

      (b)

    Percent of class:

    The Reporting Persons do not own any shares of Common Stock.                

     

      (c)

    Number of shares as to which such person has:

     

      (i)

    Sole power to vote or to direct the vote:

    None of the Reporting Persons has sole power to vote or to direct the vote of any shares of Common Stock.

     

      (ii)

    Shared power to vote or to direct the vote:

    None of the Reporting Persons has shared power to vote or to direct the vote of any shares of Common Stock.

     

      (iii)

    Sole power to dispose or to direct the disposition of:

    None of the Reporting Persons has sole power to dispose or to direct the disposition of any shares of Common Stock.

     

      (iv)

    Shared power to dispose or to direct the disposition of:

    None of the Reporting Persons has shared power to dispose or to direct the disposition of any shares of Common Stock.

    Item 5. Ownership of Five Percent or Less of a Class.

    With respect to each Reporting Person:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒.

    Item 10. Certification.

    (c) By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


    Page 6 of 7

     

    Exhibits

     

    1    Joint Filing Agreement, dated November 8, 2018, among the Reporting Persons, incorporated herein by reference to Exhibit 1 to the Original Filing.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    February 14, 2022

     

    BOXER CAPITAL, LLC
    By:  

    /s/ Aaron I. Davis

    Name:   Aaron I. Davis
    Title:   Authorized Signatory
    BOXER ASSET MANAGEMENT INC.
    By:  

    /s/ Jason Callender

    Name:   Jason Callender
    Title:   Director
    JOSEPH C. LEWIS

    /s/ Joseph C. Lewis

    Joseph C. Lewis, Individually
    Get the next $MTNB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MTNB

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MTNB
    Leadership Updates

    Live Leadership Updates

    See more
    • Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

      BEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) today announced the appointment of biotech industry veterans Keith Murphy and Edward Neugeboren to its Board of Directors as independent members, effective March 11, 2025 (the "Effective Date"). In addition, Matthew Wikler, M.D., and Natasha Giordano stepped down from the Board on the Effective Date. "We are thrilled to announce the addition of Keith and Edward to our Board," stated Jerome D. Jabbour, Chief Executive Officer of Matinas. "Their deep industry experience, leadership expertise, and capital markets acumen will be of great value as we move the company forward into a new era continu

      3/11/25 7:00:00 AM ET
      $GRCE
      $MTNB
      $ONVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Matinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors

      BEDMINSTER, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) (the "Company") today announced that the Company entered into a securities purchase agreement (the "Agreement") with a certain group of investors (the "Investors"), pursuant to which they agreed to purchase from the Company 3,300 shares of Series C Convertible Preferred Stock (the "Preferred Stock") and warrants to purchase up to 11,262,808 shares of common stock at a purchase price of $1,000 per share of Preferred Stock and accompanying warrants for aggregate gross proceeds of $3.3 million before deducting offering expenses payable by the Company. The Investors purchased 1,650 shares of

      2/13/25 5:00:00 PM ET
      $MTNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Matinas BioPharma Appoints Evelyn D'An to Board of Directors as Audit Committee Chair

      BEDMINSTER, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) today announced the appointment of Evelyn D'An to its Board of Directors as an independent director and Chair of the Audit Committee, effective Wednesday, February 5, 2025. Ms. D'An is an experienced board director and financial leader with extensive corporate governance, financial oversight, and accounting experience with a range of both public and private companies, where she has served as Chair of Audit Committees and as a member of various other board committees. Ms. D'An is also a former partner of Ernst & Young, where she spent 18 years serving clients in retail, consumer products, techn

      2/7/25 7:30:00 AM ET
      $MTNB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTNB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Matinas BioPharma downgraded by Piper Sandler

      Piper Sandler downgraded Matinas BioPharma from Overweight to Neutral

      5/11/21 8:00:37 AM ET
      $MTNB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTNB
    Financials

    Live finance-specific insights

    See more
    • Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024

      BEDMINSTER, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that it will report second quarter 2024 financial results after market close on Wednesday, August 14, 2024. Matinas management will host an investment community conference call and webcast to discuss financial results and provide a business update that day at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).   To participate in the call, please dial (866) 682-6100 (Toll-Free) or (862) 298-0702 (Toll). The webcast will be available o

      8/7/24 7:00:00 AM ET
      $MTNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024

      BEDMINSTER, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that it will report first quarter 2024 financial results after market close on Thursday, May 9, 2024. Matinas management will host an investment community conference call and webcast to discuss financial results and provide a business update that day at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).   To participate in the call, please dial 877-484-6065 (Toll-Free) or 201-689-8846 (Toll). The webcast will be available on the IR Ca

      5/2/24 7:00:00 AM ET
      $MTNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update

      Clear registration pathway and FDA agreement on the ORALTO Phase 3 trial for MAT2203 represent critical steps forward and supports partnership discussions Continued success of Compassionate/Expanded Use Access Program demonstrates potential of MAT2203 in treating multiple severe invasive fungal infections, including invasive aspergillosis Successful in vivo LNC platform studies demonstrating (a) the oral delivery of small oligonucleotides with biological activity and (b) the dramatically improved safety of LNC-docetaxel over IV-docetaxel, with similar efficacy, supports the future use of the LNC platform in inflammation and oncology Conference call begins at 4:30 p.m. Eastern time today

      3/27/24 4:05:00 PM ET
      $MTNB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTNB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Murphy Keith

      4 - Matinas BioPharma Holdings, Inc. (0001582554) (Issuer)

      5/2/25 5:19:45 PM ET
      $MTNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Neugeboren Edward

      4 - Matinas BioPharma Holdings, Inc. (0001582554) (Issuer)

      5/2/25 5:19:50 PM ET
      $MTNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Smith Robin L

      4 - Matinas BioPharma Holdings, Inc. (0001582554) (Issuer)

      5/2/25 5:19:48 PM ET
      $MTNB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTNB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

      BEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) today announced the appointment of biotech industry veterans Keith Murphy and Edward Neugeboren to its Board of Directors as independent members, effective March 11, 2025 (the "Effective Date"). In addition, Matthew Wikler, M.D., and Natasha Giordano stepped down from the Board on the Effective Date. "We are thrilled to announce the addition of Keith and Edward to our Board," stated Jerome D. Jabbour, Chief Executive Officer of Matinas. "Their deep industry experience, leadership expertise, and capital markets acumen will be of great value as we move the company forward into a new era continu

      3/11/25 7:00:00 AM ET
      $GRCE
      $MTNB
      $ONVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Matinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors

      BEDMINSTER, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) (the "Company") today announced that the Company entered into a securities purchase agreement (the "Agreement") with a certain group of investors (the "Investors"), pursuant to which they agreed to purchase from the Company 3,300 shares of Series C Convertible Preferred Stock (the "Preferred Stock") and warrants to purchase up to 11,262,808 shares of common stock at a purchase price of $1,000 per share of Preferred Stock and accompanying warrants for aggregate gross proceeds of $3.3 million before deducting offering expenses payable by the Company. The Investors purchased 1,650 shares of

      2/13/25 5:00:00 PM ET
      $MTNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Matinas BioPharma Appoints Evelyn D'An to Board of Directors as Audit Committee Chair

      BEDMINSTER, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) today announced the appointment of Evelyn D'An to its Board of Directors as an independent director and Chair of the Audit Committee, effective Wednesday, February 5, 2025. Ms. D'An is an experienced board director and financial leader with extensive corporate governance, financial oversight, and accounting experience with a range of both public and private companies, where she has served as Chair of Audit Committees and as a member of various other board committees. Ms. D'An is also a former partner of Ernst & Young, where she spent 18 years serving clients in retail, consumer products, techn

      2/7/25 7:30:00 AM ET
      $MTNB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTNB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Matinas Biopharma Holdings Inc.

      SC 13G - Matinas BioPharma Holdings, Inc. (0001582554) (Subject)

      10/25/24 9:15:12 AM ET
      $MTNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Matinas Biopharma Holdings Inc. (Amendment)

      SC 13G/A - Matinas BioPharma Holdings, Inc. (0001582554) (Subject)

      2/14/22 4:43:03 PM ET
      $MTNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Matinas BioPharma Holdings, Inc. (0001582554) (Subject)

      2/16/21 5:01:52 PM ET
      $MTNB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTNB
    SEC Filings

    See more
    • SEC Form PRE 14A filed by Matinas Biopharma Holdings Inc.

      PRE 14A - Matinas BioPharma Holdings, Inc. (0001582554) (Filer)

      5/5/25 8:49:22 AM ET
      $MTNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Matinas Biopharma Holdings Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Leadership Update, Shareholder Director Nominations, Other Events, Financial Statements and Exhibits

      8-K - Matinas BioPharma Holdings, Inc. (0001582554) (Filer)

      5/2/25 5:15:07 PM ET
      $MTNB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Matinas Biopharma Holdings Inc.

      EFFECT - Matinas BioPharma Holdings, Inc. (0001582554) (Filer)

      4/30/25 12:15:21 AM ET
      $MTNB
      Biotechnology: Pharmaceutical Preparations
      Health Care